Skip to content
Open in App
Genmab logo

Genmab

web2

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates fo...

Symbol · GMAB
Company profile

About

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

People

Company team

PE

Pernille Erenbjerg

Independent Deputy Chairman

Company leadership profile.

RK

Rolf Karl-Heinz Hoffmann

Independent Director

Company leadership profile.

DP

Deirdre P. Connelly

Independent Chairman of the Board

Company leadership profile.

MS

Martin Schultz

Senior Director, Head of Development Business Partnership & Strategy and Director

Company leadership profile.

MZ

Mijke Zachariasse

VP, Head of Antibody Research Materials & Director

Company leadership profile.

TH

Takahiro Hamatani

Senior Director of Finance Japan & Non-Independent Director

Company leadership profile.

MK

Michael Kavanagh

Senior Director, Head of Strategic Engagement & Oncology Marketing and Non-Independent Director

Company leadership profile.

AG

Anders Gersel Pedersen

Non-Independent Director

Company leadership profile.

EG

Elizabeth G. O'Farrell

Independent Director

Company leadership profile.

PP

Paolo Paoletti

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated Genmab.

Orbitrum research

Experts evaluating Genmab

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment